Close Menu

NEW YORK (GenomeWeb) – Interpace Diagnostics Group announced today that it has executed a new agreement with Laboratory Corporation of America that will expand the network of cytology providers in support of its thyroid molecular business unit.

Under the new agreement, physicians will be able to order both thyroid biopsy analysis and molecular testing from Interpace, and LabCorp's Dianon Pathology, will be available to do biopsy analysis. In the event of an indeterminate result, Interpace will perform its molecular test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
10

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.